Adaptimmune Appoints Lawrence M. Alleva to its Board of Directors
News Mar 11, 2015
Adaptimmune has announced the appointment of Lawrence (Larry) M. Alleva, to its Board of Directors as an independent, non-executive director with immediate effect. Mr. Alleva will also serve as chairman of the Board Audit Committee.
Mr. Alleva is a former partner with PricewaterhouseCoopers LLP (PwC), where he worked for 39 years until his retirement in June 2010, including 28 years’ service as a partner. Mr. Alleva worked with numerous pharmaceutical and biotechnology companies as clients and, additionally, served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firm’s Assurance Practice from 2006 until his retirement.
Mr. Alleva currently serves as a director for public companies Tesaro Inc. and Bright Horizons Family Solutions Inc., and for privately held Mirna Therapeutics Inc., and chairs the audit committee for those companies. He previously served on the board of GlobalLogic, Inc. through the sale of the company in 2013 and also chaired the audit committee. Mr. Alleva is a Certified Public Accountant (inactive). He received a Bachelor of Science degree in Accounting from Ithaca College and attended Columbia University’s Executive MBA non-degree program.
“I am delighted that such a high caliber individual as Larry Alleva has agreed to join our Board of Directors,” said Dr. Jonathan Knowles, Chairman of Adaptimmune. “His substantial corporate finance and accounting expertise, combined with his extensive experience of supporting growing biotech firms, brings significant added value to the Company, and complements the skills and experience of our other Board members.”
Mr. Alleva said: “I am very pleased to be joining Adaptimmune at this interesting time, and I look forward to working closely with the team as we aim to build the Company up with the expansion of its UK and US operations.”
Being Born During a Flu Pandemic May Increase Your Risk of Death During Another Flu PandemicNews
While past exposure to influenza A viruses often builds immunity to similar, and sometimes different, strains of the virus, researchers are calling for more attention to exceptions to that rule.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE
Stainless Steel That Is More Resistant to BacteriaNews
Stainless steel is widely used in surgical instruments and implants but over time, implants can be rejected by the body and in unhygienic surgical environments, steel may not adequately resist the accumulation of harmful bacteria. However, scientists have now developed a way to modify the surface of the stainless steel by creating a set of pores at the nanoscale. The improved material could benefit the food and beverage industry as well as medicine.READ MORE